Cholestech (CTEC) Receives FDA CLIA Waived Status for New Combined Test Panel
More News related to CTEC
- China Agritech Receives Approval for NASDAQ Listing; New Symbol "CAGC"
- Cholestech (CTEC) Receives FDA CLIA Waived Status for New Combined Test Panel
- Stifel Nicolaus Upgrades Inverness Medical Innovations (IMA) to Buy
- StreetInsider.com Unusual 11 Mid-Day Movers 06/04/2007
- Inverness Medical Innovations (IMA) to Acquire Cholestech (CTEC)
More News related to FDA
- National Bank of Greece (NBG) To Elect New Board Members on December 2
- Stocks Hit On Dubai Fallout
- Gold Hit As Dubai Woes Sends Dollar Higher
- As Economy Shows Improvement, Banks' Financing More - WSJ (JPM, C, GS, DB, CS, More)
- Dubai Debt Woes Roil Markets
Cholestech Corporation (Nasdaq: CTEC) announces that the FDA has granted CLIA waived status to the Company's newest test panel, Lipid Profile ALT. The new test panel, designed for use with the Cholestech LDX® System, combines an ALT test with a lipid profile, providing total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride and alanine aminotransferase (ALT) results from a single fingerstick.
By testing at the point of care, the Lipid Profile ALT test allows physicians in the US to immediately assess elevated cholesterol levels and liver damage at the same time allowing for medication dosage adjustments and safety monitoring on-the-spot.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
